Genscript Biotech Full Year 2023 Earnings: EPS Beats Expectations

Simply Wall St · 2024-04-25 18:42

Genscript Biotech (HKG:1548) Full Year 2023 Results

Key Financial Results

Revenue: US$839.5m (up 34% from FY 2022).
Net loss: US$95.5m (loss narrowed by 58% from FY 2022).
US$0.045 loss per share (improved from US$0.11 loss in FY 2022).

revenue-and-expenses-breakdown — SEHK:1548 Revenue and Expenses Breakdown April 25th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Genscript Biotech EPS Beats Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 56%.

The primary driver behind last 12 months revenue was the Life Science Services and Products segment contributing a total revenue of US$412.9m (49% of total revenue). Notably, cost of sales worth US$430.0m amounted to 51% of total revenue thereby underscoring the impact on earnings. The largest operating expense was Research & Development (R&D) costs, amounting to US$432.8m (52% of total expenses). Over the last 12 months, the company's earnings were enhanced by non-operating gains of US$320.3m. Explore how 1548's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Life Sciences industry in Asia.

Performance of the market in Hong Kong.

The company's shares are down 6.1% from a week ago.

Valuation

Genscript Biotech's financial results now indicate the company's shares could present an opportunity based on 6 important indicators. Click here to find out what a fair price for the stock might be and where analysts see the share price heading over the next year.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.